Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4571049 | 0.97 | HPGDS (0.30) | HPGDS | |
| SCHEMBL4571055 | 0.97 | HPGDS (0.30) | HPGDS | |
| SCHEMBL4571051 | 0.97 | HPGDS (0.30) | HPGDS | |
| SCHEMBL4571053 | 0.97 | MC4R (0.35) | MC4R | |
| SCHEMBL4571047 | 0.97 | MC4R (0.35) | MC4R | |
| SCHEMBL2684690 | 0.92 | PIK3R1 (0.30) | PIK3R1PIK3CAHDAC1 | |
| SCHEMBL3164307 | 0.91 | MTNR1A (0.34) | HPGDSPIK3R1PIK3CAHDAC1 | |
| SCHEMBL4571056 | 0.89 | MC4R (0.34) | MC4R | |
| SCHEMBL4571052 | 0.89 | MC4R (0.34) | MC4R | |
| SCHEMBL4571054 | 0.89 | MC4R (0.34) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404728-B2 | Small-molecule botulinum toxin inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120114696-A1 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | US ARMY, SECRETARY OF THE ARMY | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114696-A1 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | BTD, BCHE, ACHE | MC4R 3537/4885HPGDS 1531/4885PIK3R1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.